

# Luis Lara-Mejía

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1485925/publications.pdf>

Version: 2024-02-01

12  
papers

81  
citations

1683934

5  
h-index

1474057

9  
g-index

12  
all docs

12  
docs citations

12  
times ranked

130  
citing authors

#	ARTICLE	IF	CITATIONS
1	Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study. <i>Lung Cancer</i> , 2021, 152, 119-126.	0.9	17
2	Association of Carcinoembryonic Antigen Reduction With Progression-free and Overall Survival Improvement in Advanced Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, 510-522.	1.1	5
3	Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells. <i>Pathology and Oncology Research</i> , 2021, 27, 597499.	0.9	2
4	Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease. <i>Lung Cancer</i> , 2021, 155, 183-190.	0.9	8
5	RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin. <i>BMC Cancer</i> , 2021, 21, 892.	1.1	3
6	Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs. <i>Cancer Biomarkers</i> , 2021, 32, 1-13.	0.8	2
7	Clinical Impact of the COVID-19 Pandemic in Mexican Patients with Thoracic Malignancies. <i>Oncologist</i> , 2021, 26, 1035-1043.	1.9	6
8	Brigatinib in <i>ALK</i> -positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP). <i>Future Oncology</i> , 2021, 17, 169-181.	1.1	5
9	Locoregional control and toxicity after pleurectomy/decortication and intensity-modulated pleural radiation therapy in patients with malignant pleural mesothelioma. <i>Thoracic Cancer</i> , 2020, 11, 3448-3455.	0.8	1
10	Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103033.	2.0	17
11	Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations. <i>BMC Cancer</i> , 2020, 20, 829.	1.1	11
12	Carboplatin plus etoposide or topotecan for small-cell lung cancer. <i>Lancet Oncology</i> , The, 2020, 21, 1132-1134.	5.1	4